Neion Bio

What Neion Bio does

Neion Bio, Inc. is a Delaware-incorporated biotechnology company founded in 2024, headquartered at the Ford Center Incubator at Rockefeller University in New York City, with an 11–50 employee base. The company has developed the Raptor™ platform, an egg-based biomanufacturing system that uses genetically engineered chickens to produce recombinant biologics — including monoclonal antibodies, multi-specifics, enzymes, cytokines, fusion proteins, and peptides — directly in egg whites. The approach replaces expensive, hard-to-scale mammalian cell-culture facilities with living bioreactors that operate on grain and water as inputs, with the company claiming up to 10x lower cost of goods sold, up to 100x lower capital expenditure versus $1–2 billion traditional plants, ultra-low batch-to-batch variability, and 10–100x lower carbon footprint.

The business model is B2B contract biomanufacturing and co-development. Neion Bio monetizes through co-development and supply agreements with pharmaceutical and biotech partners that include upfront payments, development and regulatory milestones, and long-term profit participation on commercialized products. Its first commercial agreement, announced in March 2026, is a co-development and supply deal with a major global pharmaceutical company covering up to three monoclonal antibodies. The company explicitly targets four horizontal customer segments — biosimilars, biotech, animal health, and reagents — selling into a biosimilar patent cliff that IQVIA estimates represents a $232 billion addressable opportunity across 118 biologics losing exclusivity between 2025 and 2034.

To date Neion Bio has raised approximately $34 million across two rounds: an approximately $11 million seed in 2024 led by Caffeinated Capital with Basis Set Ventures and Haystack VC, and an oversubscribed $23 million Series A in June 2026 led by Caffeinated Capital. The leadership team combines commercial biopharma veterans — including Ming Li, the former Alvotech CSO who led its IPO — with genome engineering and avian biology expertise sourced from Colossal Biosciences, Oxford, MIT, McGill, Boston College, and Purdue, positioning the company to translate a frontier biology platform into commercial-scale biomanufacturing partnerships.

Name

Neion Bio

Legal name

Neion Bio, Inc.

Website

https://neionbio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Co-development and Supply Agreements: Neion Bio generates revenue through co-development and supply agreements with pharmaceutical partners. The first agreement covers up to three monoclonal antibodies and includes upfront payments, milestone payments (clinical and regulatory), and long-term profit participation. This provides near-term revenue through development fees and long-term revenue through profit sharing on commercialized products.
2. Biologics Manufacturing Services: The company manufactures biologics including monoclonal antibodies, multi-specifics, enzymes, cytokines, fusion proteins, and peptides for therapeutic or non-therapeutic use at any scale, with site flexibility and rapid ramp-up capabilities. Revenue derived from manufacturing services for partners.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Neion Bio provides contract biomanufacturing and co-development services for recombinant biologics using its Raptor™ platform, which employs genetically engineered chickens as living bioreactors that produce complex proteins (monoclonal antibodies, multi-specifics, enzymes, cytokines, fusion proteins, peptides) directly in egg whites. Customers enter into co-development and supply agreements that include upfront payments, development and regulatory milestones, and long-term profit participation on commercialized products. The platform targets biosimilar, biotech, animal health, and reagent companies with up to 10x lower COGS and 100x lower CapEx than traditional mammalian cell culture manufacturing.

Product overview

Neion Bio is a biotechnology company that has developed the Raptor™ Platform, an egg-based biomanufacturing system that uses genetically engineered chickens to produce recombinant biologics in egg whites. The platform is a core manufacturing technology that enables production of monoclonal antibodies, enzymes, fusion proteins, peptides, cytokines, and multi-specific proteins. The company offers contract manufacturing services for therapeutic and non-therapeutic applications, serving biosimilar, biotech, animal health, and reagents companies. The platform reportedly offers up to 10x lower cost of goods and up to 100x lower capital expenditure compared to traditional mammalian cell culture facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Raptor™: The company's core technology platform that uses genetic engineering to produce biologics in genetically engineered chicken eggs, enabling scalable and low-cost protein manufacturing.

Products and services

• Raptor™ Platform Core biomanufacturing platform that uses genetically engineered chickens as living bioreactors to produce recombinant biologics in egg whites. Customers contract with Neion Bio to leverage the platform for therapeutic or non-therapeutic protein manufacturing with significantly lower cost of goods and capital intensity than traditional mammalian cell culture.
• Biologics Contract Manufacturing Services Contract manufacturing services using the Raptor platform to produce biologics including monoclonal antibodies, multi-specifics, enzymes, cytokines, fusion proteins, and peptides for therapeutic or non-therapeutic use, at any scale with site flexibility and rapid ramp-up. Includes upfront payments, development and regulatory milestones, and long-term profit participation.
• Biosimilar Co-Development and Manufacturing Services Co-development and manufacturing services targeted at biosimilar companies seeking lower-cost versions of approved biologic medicines. Enables biosimilar development for molecules beyond blockbuster biologics due to reduced development costs, with access to capabilities and capacity requiring minimal investment.

Quantifiable outcome

• Up to 10x lower cost of goods sold (COGS) compared to traditional cell-culture-based biomanufacturing
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Major Global Pharmaceutical CompanyflagshipStrategic or Co-development Partner · 26 March 2026Neion Bio's first major co-development and supply agreement with a major global pharmaceutical company for the co-development and supply of up to three monoclonal antibodies. The agreement includes upfront payments, milestone payments, and long-term profit participation. This strategic partnership validates the Raptor™ platform's potential to revolutionize biomanufacturing.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Samsung Biologics: Samsung Biologics is a major Korean biologics CDMO operating large-scale mammalian cell culture facilities globally. Broad incumbent representing the entrenched, capital-intensive model Neion Bio aims to disrupt with its lower-CapEx egg-based platform.
• Catalent: Catalent is a global CDMO providing development and manufacturing services for biologics, including monoclonal antibodies, enzymes, and fusion proteins. Broad incumbent and a representative large CDMO whose traditional mammalian manufacturing footprint Neion Bio's Raptor™ platform is designed to undercut.
• Lonza: Lonza is the world's largest biologics CDMO, operating mammalian cell culture facilities and offering end-to-end development and manufacturing services to pharma. Broad incumbent whose traditional cell culture infrastructure Neion Bio positions itself against on cost, scale, and localization.
• WuXi Biologics: WuXi Biologics is one of the largest global biologics CDMOs with extensive mammalian cell culture capacity across multiple geographies. Broad incumbent and primary competitive benchmark for cost and capacity in the biologics manufacturing services market Neion Bio targets.

Direct peers

• Resilience: Resilience is a technology-focused biomanufacturing CDMO building novel capacity for biologics, vaccines, and cell therapies. Comparable as an emerging CDMO competing with entrenched players by offering modern, lower-cost manufacturing infrastructure to pharma partners.
• Ginkgo Bioworks: Ginkgo operates a synthetic biology platform that programs cells (microbial and mammalian) for customers across pharma, food, and industrial biotech. It is a direct peer as a cell engineering CDMO whose business model is selling platform-enabled biomanufacturing capacity to large customers.
• Alvotech: Alvotech is a pure-play biosimilar developer and manufacturer that went public with leadership from Ming Li (now Neion's President of Commercial). It is a direct peer on the biosimilar demand side and a credible strategic partner/customer profile for Neion's Raptor™ platform.
• Pharming Group: Pharming is a Dutch biotech that produces therapeutic proteins using a transgenic rabbit platform (e.g., Ruconest for hereditary angioedema). It is the most commercially validated analog to Neion Bio: both use genetically engineered animals as living bioreactors to manufacture recombinant biologics at lower cost than mammalian cell culture. Direct peer for platform category and business model.
• Alexion (AstraZeneca Rare Disease): Alexion acquired Synageva BioPharma, which pioneered transgenic chicken egg-based production of therapeutics (e.g., Kanuma/sebelipase alfa for LAL deficiency). It is the only prior commercial precedent for an egg-based biologics platform and the closest historical analogue to Neion Bio's Raptor™ technology.
• Codexis: Codexis engineers enzymes and biocatalysts for pharmaceutical manufacturing, including protein therapeutics. Comparable as a technology-driven company selling engineered biological platforms to reduce cost and improve sustainability of drug manufacturing processes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neion-bio-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neion Bio